Activity Summary:
Patients with relapsed/refractory multiple myeloma (RRMM) are associated with poor survival outcomes and are in continual need of more effective therapies. Currently, a multitude of agents including monoclonal antibodies, proteosome inhibitors, immunomodulatory agents, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and selinexor are available for patients with RRMM. More recently, the bispecific antibodies, teclistamab, elranatamab, and talquetamab have been approved for the treatment of RRMM and are also under investigation in combination with other agents and in different settings of MM.

In this podcast series, leading experts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.

Activity Summary:
Patients with relapsed/refractory multiple myeloma (RRMM) are associated with poor survival outcomes and are in continual need of more effective therapies. Currently, a multitude of agents including monoclonal antibodies, proteosome inhibitors, immunomodulatory agents, bispecific antibodies, chimeric antigen receptor (CAR) T-cell therapy, and selinexor are available for patients with RRMM. More recently, the bispecific antibodies, teclistamab, elranatamab, and talquetamab have been approved for the treatment of RRMM and are also under investigation in combination with other agents and in different settings of MM.

In this roundtable discussion, leading experts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.

Activity Summary:
Heart failure (HF) is a complex syndrome and a growing problem, in terms of both the number of patients affected, its associated clinical consequences and its implications for health care expenditure. HF is recognized as the ultimate pathway of cardiovascular disease (CVD). Importantly, rapid ageing of the population means that the incidence of HF shall increase further in the coming years. Preventing the development of this condition in the population at large, in order to reduce hospital readmission rates, its other clinical sequelae and its economic consequences, is a key issue in modern medicine. Appropriate HF treatment can have the greatest influence on prolonging patients' lives in the coming year. Typically, HF is a common and insidious disease with substantial associated morbidity and mortality burden worldwide. This has led to a significant focus on improving treatments and medical therapy for this condition.

This podcast will provide expert interpretation of recent clinical trial evidence for CV risk reduction in people with HF, examining results of new therapeutic approaches for the treatment of HF presented at the 73rd Annual Scientific Session & Expo of American College of Cardiology (ACC 2024), April 6-8, Atlanta, GA.

Activity Summary:
Heart failure (HF) is a complex syndrome and a growing problem, in terms of both the number of patients affected, its associated clinical consequences and its implications for health care expenditure. HF is recognized as the ultimate pathway of cardiovascular disease (CVD). Importantly, rapid ageing of the population means that the incidence of HF shall increase further in the coming years. Preventing the development of this condition in the population at large, in order to reduce hospital readmission rates, its other clinical sequelae and its economic consequences, is a key issue in modern medicine. Appropriate HF treatment can have the greatest influence on prolonging patients' lives in the coming year. Typically, HF is a common and insidious disease with substantial associated morbidity and mortality burden worldwide. This has led to a significant focus on improving treatments and medical therapy for this condition.

This clinical clip will provide expert interpretation of recent clinical trial evidence for CV risk reduction in people with HF, examining results of new therapeutic approaches for the treatment of HF presented at the 73rd Annual Scientific Session & Expo of American College of Cardiology (ACC 2024), April 6-8, Atlanta, GA.

Activity Summary:
We are pleased to have recently held the Optimal Management of HIV Disease & Hepatitis: Clinical Conference XXXII (OPMAN). The conference took place March 16-17, 2024, in Baltimore, Maryland with leading clinicians and researchers presenting an array of topics covering HIV disease and liver disease. The presentations offered a unique distillation of clinically focused data tailored for practicing HIV and hepatitis healthcare professionals.

These accredited video archives of OPMAN XXXII provide access to each day of the conference, including clinical presentations, interactive case discussions, and panel discussions addressing audience questions. Continuing education credit is provided for each segment, so you may participate in your area(s) of interest. We hope you enjoy this activity!

Activity Summary:
Adolescents are disproportionately affected by HIV, accounting for approximately one in five new HIV infections in the United States. The expanded options for pre-exposure prophylaxis (PrEP) in adolescents provides clinicians with additional, effective tools to further reduce the risk of HIV transmission in this group. Once diagnosed, youth with HIV are the least likely out of any age group to be linked to care and achieve viral suppression once on ART.

In this Lecture Library Dr. Fields reviews factors that increase HIV risk in adolescents, HIV/STI screening and prevention considerations in adolescents, and key considerations when prescribing HIV PrEP to adolescents along with the most recent data from AIDS 2024, the 25th International AIDS Conference, and IDWeek 2024.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
One key strategy for ending the HIV epidemic in the United States is the rapid and large scale-up of pre-exposure prophylaxis (PrEP) provision by clinicians providing health care to HIV-uninfected persons at risk for HIV acquisition.

In this Lecture Library Dr. Kelley reviews HIV testing for people considering or taking PrEP, STI prevention and PrEP, and approaches to implementing and follow-up care for your patients on PrEP along with the most recent data from AIDS 2024, the 25th International AIDS Conference.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
The Simply Speaking HIV Prevention lecture series includes a curriculum that highlights the very latest clinical data utilizing a PowerPoint slide presentation developed and approved by key expert physicians and further reviewed and approved by the Planning Committee. The slides will be continuously evaluated and updated for current relevance.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" videos from data presented at CROI 2024.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" videos from data presented at CROI 2024.

Activity Summary:
Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).

Activity Summary:
Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this webcast archive, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).

Activity Summary:
Conversations in Hematology/Oncology: Incorporating Key Updates in the Treatment of Follicular Lymphoma: A Discussion Following ASH 2023 on Assimilating Practice-Changing Breakthroughs is a podcast discussion between key opinion leaders to identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.

Activity Summary:
Myelofibrosis (MF) is a complex myeloproliferative neoplasm (MPN) that profoundly impacts the lives of patients. Recent years have witnessed advancements in risk stratification, symptom management, and treatment options for patients with MF. Unmet needs include alleviation of limiting thrombocytopenia and anemia, halting disease progression to acute leukemia, and extending survival. This has stimulated the development and investigation of a number of new agents for MF treatment. This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).

Activity Summary:
Conversations in Hematology/Oncology: Incorporating Key Updates in the Treatment of Follicular Lymphoma: A Discussion Following ASH 2023 on Assimilating Practice-Changing Breakthroughs is a discussion between key opinion leaders to identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.

Activity Summary:
New frontiers for HIV therapy continue to be explored, as underscored by the clinical development and use of new agents, changing regimen strategies and development of long-acting novel agents. This expanding era of simplified and effective HIV therapy presents physicians with many new opportunities and challenges for providing care. To deliver state-of-the-art HIV prevention and care, healthcare providers must stay informed regularly of new clinical data and treatment recommendations in HIV.

This educational Quarterly Brief, covering HIV data from October through December of 2023, will discuss the most clinically relevant information on HIV Prevention, ART Studies, and Comorbidities.

Activity Summary:
Conversations and Cases in Oncology: Practice-Changing Updates in Systemic Treatment of Advanced Hepatocellular Carcinoma (HCC) is a roundtable discussion between leading experts to inform and guide on key updates. The expert faculty, Dr. Adam Burgoyne, Dr. Rachna Shroff and Dr. Mark Yarchoan, will discuss recent progress in different treatment settings of advanced HCC and provide insights into integrating new evidence into practice.

This activity will be supported by supplemental, downloadable slides as an educational resource.

Activity Summary:
Myelofibrosis (MF) is a complex myeloproliferative neoplasm (MPN) that profoundly impacts the lives of patients. Recent years have witnessed advancements in risk stratification, symptom management, and treatment options for patients with MF. Unmet needs include alleviation of limiting thrombocytopenia and anemia, halting disease progression to acute leukemia, and extending survival. This has stimulated the development and investigation of a number of new agents for MF treatment. This Conversations in MF will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).

The activity is supported by downloadable slides that have key discussion and teaching points.

Activity Summary:
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO is a podcast discussion between leading experts to inform and guide the safety and efficacy of trophoblast cell-surface antigen-directed antibody-drug conjugates (TROP2-directed ADCs) in different settings of non-small cell lung cancer (NSCLC) treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

Activity Summary:
Immune thrombocytopenia (ITP) is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation. Due to low levels of platelets, ITP is associated with frequent bruising and bleeding. Current evidence suggests that low platelet counts in ITP are the result of multiple factors. Heterogeneity in patient population and characteristics make it challenging for the clinicians to choose appropriate therapeutic regimen. Clinicians must make decisions on the basis of the clinical presentation of each individual patient, ideally through a shared decision-making process that considers the patient’s values and preferences with respect to the anticipated outcomes of the chosen option.

During this accredited continuing education series of four (4) podcasts, Dr. James Bussel and Dr. Cindy Neunert discuss emerging evidence for management strategies for ITP, including utilization of patient reported outcomes and shared decision making to improve outcomes.

Activity Summary:
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO is a roundtable discussion between leading experts to inform and guide the safety and efficacy of trophoblast cell-surface antigen-directed antibody-drug conjugates (TROP2-directed ADCs) in different settings of non-small cell lung cancer (NSCLC) treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

This activity is supported by downloadable slides that have the key discussion and teaching points.

Activity Summary:
Conversations in Acute Myeloid Leukemia: Novel Therapies Targeting the Immune System for Elderly/Unfit Patients is a podcast series between leading experts to inform and guide on breakthroughs and practice-changing updates. The expert faculty will discuss unmet needs in the treatment of elderly/unfit patients with AML and the role of novel therapies targeting the immune system in addressing them.

Activity Summary:
In this podcast series, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Conversations in Acute Myeloid Leukemia: Novel Therapies Targeting the Immune System for Elderly/Unfit Patients is a roundtable discussion between leading experts to inform and guide on breakthroughs and practice-changing updates. The expert faculty will discuss unmet needs in the treatment of elderly/unfit patients with AML and the role of novel therapies targeting the immune system in addressing them.

The activity is supported by downloadable slides that have the key discussion and teaching points.

Activity Summary:
Clinical Clips are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. This activity is designed to keep healthcare professionals on top of the most recent clinical findings.

This certified AMA/ABS/ANCC enduring video and podcast will spotlight latest advances in the treatment of ITP through a 'what you need to know' video featuring a leading expert reporting from the 2023 ASH Conference.

Activity Summary:
Talking PsA is a podcast series that highlights the very latest clinical data in Psoriatic Arthritis. This activity includes management strategies and case-based topics to help clinicians select the most appropriate treatment, as well as address the significant health burdens and complications experienced by many patients during treatment.

Activity Summary:
In this webcast archive, Dr. Scott Canna and Dr. Alexei Grom discuss diverse mechanisms and clinical presentations in patients with suspected MAS, approaches for the timely diagnosis of MAS, and considerations for appropriate treatment and management strategies.

Activity Summary:
Immune thrombocytopenia (ITP) is an autoimmune disorder defined by a significantly reduced number of platelets in blood circulation. Due to low levels of platelets, ITP is associated with frequent bruising and bleeding. Current evidence suggests that low platelet counts in ITP are the result of multiple factors. Heterogeneity in patient population and characteristics make it challenging for the clinicians to choose appropriate therapeutic regimen. Clinicians must make decisions on the basis of the clinical presentation of each individual patient, ideally through a shared decision-making process that considers the patient’s values and preferences with respect to the anticipated outcomes of the chosen option.

In this webcast archive, Dr. James Bussel and Dr. Cindy Neunert discuss emerging evidence for management strategies for ITP, including utilization of patient reported outcomes and shared decision making to improve outcomes.

Activity Summary:
Talking COPD is a webcast series that highlights the very latest clinical data in chronic obstructive pulmonary disease. Slides are developed and presented by leading COPD expert physicians and further reviewed and approved by the planning committee.

Chronic obstructive pulmonary disease (COPD) imposes significant impact beyond the lungs, including quality of life, health status, daily activities, physical activity, sleep, and comorbidities such as anxiety and depression. Given the increasing recognition of, and importance attributed to, patients’ and caregivers’ views and preferences on their disease and its management, it is important to identify and understand patients’ perception of COPD symptoms. Additionally, diagnosis and treatment of COPD are rapidly changing. In this on-demand video presentation, our expert faculty review how the understanding and implementation of recent advances is important for delivering optimal patient care.

Activity Summary:
Talking PsA is a webcast archive that highlights the very latest clinical data in Psoriatic Arthritis. Slides are developed and presented by leading Rheumatology and Dermatology experts and further reviewed and approved by the planning committee.

This activity includes case-based topics on management strategies for patients with PsA as well as clinical discussions by leading PsA experts.